Navigation Links
Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
Date:4/17/2008

WOODCLIFF LAKE, N.J., April 17 /PRNewswire/ -- Eisai Corporation of North America today announces the immediate appointment of Robert Laverty as Vice President of U.S. Corporate Communications. In this newly created position, Mr. Laverty will be responsible for overseeing and coordinating all of Eisai's corporate communications strategies and activities in the United States.

Mr. Laverty brings to Eisai more than 22 years of global corporate, product, policy and research and development communications experience in the pharmaceutical industry. Most recently, he served as Vice President, Global Communications, Malaria Initiatives for Novartis AG, where he oversaw all global communications supporting the company's malaria initiative in the developing world. In addition, Mr. Laverty has held several other executive titles at Novartis Pharmaceuticals Corp, including Vice President, External Communication and Vice President, Global Pharma Media Relations.

Earlier in his career, Mr. Laverty held a number of progressively responsible positions in corporate policy, corporate affairs, and product public affairs at Bristol-Myers Squibb Company. He holds a Bachelor of Science degree in pharmacy from St. John's University, Jamaica, New York.

"Mr. Laverty is a welcome addition to our company and will be instrumental in strengthening Eisai's visibility and presence in the U.S. as a top-20 pharmaceutical company," said Lonnel Coats, President & COO, Eisai Corporation of North America. "With his more than two decades of senior communications expertise in the global pharmaceutical industry, Mr. Laverty's contributions to our company will be invaluable, as we continue to fulfill our human health care (hhc) mission to satisfy unmet medical needs and increase benefits to patients and their families."

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, Inc., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery. For more information about Eisai, please visit http://www.eisai.com.


'/>"/>
SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DARA Announces Surgi-Vision Agreement with Boston Scientific Corporation
2. Torchmark Corporation Reports First Quarter 2008 Results
3. Digirad Corporation to Release First Quarter Financial Results on April 24, 2008
4. Otter Tail Corporation Holds 2008 Annual Meeting: Shareholders Elect Directors; Board Declares Quarterly Dividend
5. Microflex Corporation Launches New Website
6. Linkwell Corporation Selected to Train and License all Disinfectant and Pest Control Professionals in China and for the Beijing Olympics
7. Zipfizz(R) Announces Distribution Deal With the Odom Corporation
8. Alsius Corporation Awarded Three-Year Agreement With MedAssets Supply Chain Systems
9. BioElectronics Corporations New Commercial Airing Nationally Advertising Initiative Will Reach 15,000,000 Homes Nationwide
10. Linkwell Corporation Year-End 2007 Earnings Release and Conference Call Notice
11. Albemarle Corporations First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 8:00am ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... ... Social media marketing is transitioning from a singular person activity to a ... into this insight and more in its latest episode of its Brains Over Brawn ... with social media strategist and partner of the digital firm Med|Ed Digital Jessica Columbo. ...
(Date:2/22/2017)... ... 22, 2017 , ... In a recent article ... context (age, illness and life choices) should be dissociated from medical errors and ... In addition, all too often, studies regarding health system performance in other countries, ...
(Date:2/21/2017)... ... 22, 2017 , ... Author Michèle Wolff has a passion for using ... to know all about it for optimal health. Wanting to share her knowledge to ... Digestive and Wellness Solutions ” (published by Balboa Press AU). , This book ...
(Date:2/21/2017)... ... ... Doctors on Liens has announced the addition of Mendonca Spine Care Center ... network of doctors in Central and Northern California. Dr. Mendonca specializes in personal injury ... pain, neck pain, hip and knee pain, and headaches. Specializing in non-surgical, spinal ...
(Date:2/21/2017)... ... February 21, 2017 , ... Support of value-based care models requires collaboration across ... data across industry solutions, Fogo Data Centers announces the launch of the Fogo Partner ... community is one in which all systems work well, work together, and work together ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)...  Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical ... the field of urology, today announced the expansion of ... managers from 35 currently, a 20% increase in the ... expansion is being driven by the increasing growth of ... increasing acceptance of Natesto,s unique product profile and clinical ...
(Date:2/22/2017)... February 22, 2017 NetworkNewsWire Editorial Coverage: The ... states in the U.S. have now legalized marijuana for medicinal or ... Canada , Jamaica , ... Portugal , Uruguay and ... decriminalize cannabis in the last two years. As a result, the ...
(Date:2/22/2017)... , Feb. 22, 2017 Kineta, Inc., ... of novel immune modulating therapies, today announced that ... nicotinic acetylcholine receptor (nAChR), demonstrates robust chronic pain ... models. The study also establishes the a9a10 nAChR ... of chronic pain. The findings were reported online ...
Breaking Medicine Technology: